Tesaro Pumped As PARP Inhibitor Zejula Gets CHMP Nod

While AstraZeneca's rival drug Lynparza is catching up across the Atlantic, this likely approval for Tesaro's ovarian cancer drug will boost the US firm as it aims to make a strong start in the European market.